Today's Radar: Low Float (Nasdaq: OPTH) Aims For Disruption In A Forecasted $11.7Bn Market

Most companies working with psych-e-delic compounds are still waiting.

Any content you receive is for information purposes only. Always conduct your own research. *Disseminated on Behalf of Optimi Health Corp. Today's Radar: Low Float (Nasdaq: OPTH) Aims For Disruption In A Forecasted $11.7Bn Market *Get Our Updates Faster—Tap Here To Receive SMS Alerts* September 10th Greetings, Friend! Most companies working with psych-e-delic compounds are still waiting. Waiting on trial readouts. Waiting on regulators. Waiting on a first paying customer. Inside a licensed facility in Princeton, British Columbia, a different clock runs. Capsules come off a validated line, clear Health Canada export authorization, and reach prescribing physicians on the other side of the world. The company behind that line has spent 2026 stepping into a wider view. On September 8th, 2026, Optimi Health Corp. (Nasdaq: OPTH) said it will present at H.C. Wainwright’s 28th Annual Global In-vest-ment Conference in New York, running September 14th to 16th. For a name that spent years as a Canadian small cap, that is a change of altitude. The groundwork was laid in the spring. On May 20th, 2026, the company priced an oversubscribed $15Mn public offering at $6.25 per share and joined the Nasdaq Capital Market under the ticker OPTH. Stated uses included scaling production, U.S. expansion, and working capital. What separates this name from the field is the sales ledger. Australia was the first country to reschedule psi-lo-cybin for treatment resistant depression, in July 2023. Since launching 5mg capsules there in September 2025, the company has completed three commercial shipments, the latest covering 1,000 capsules. More than 750 clinicians have been trained to deliver the treatment, and the treatment is reimbursed by payers including the Department of Veterans’ Affairs and Medibank.  Then came the second channel. On June 10th, 2026, the company shared it completed its first psi-lo-cybin export to the United Kingdom for a Phase 2 clinical trial, shipping biomass, and finished 5mg capsules under Health Canada export and UK Home Office import authorizations. The backdrop keeps widening. Grand View Research estimated the global psych-e-delic drugs market at $4.1Bn in 2025, growing at a 14.1% compound annual rate toward $11.7Bn by 2033. About The Company: Optimi Health Corp. Optimi Health Corp. is a commercial stage manufacturer of regulated psych-e-delic drug products. It runs a Health Canada GMP compliant facility in Princeton, British Columbia under a Drug Establishment Licence covering commercial manufacture, packaging, testing and international export. Revenue has been recognized since the second quarter of 2024. The line is built on finished dose capsules: botanical psi-lo-cybin extract, validated GMP grade M-D-M-A, and a natural microdose range extended on June 16th, 2026, with standardized 1mg and 2mg capsules for clinical research organizations. Sales come from regulated access programs, currently Australia’s Authorized Prescriber Scheme and Canada’s Special Access Program, plus trial sponsors. Behind The Scenes Company commentary this year has stayed plain spoken. On the UK shipment, Company CEO, Dane Stevens, framed the structural point directly: “We can serve a commercial market and a clinical trial from the same GMP facility, on our own licence. That is a rare position.” On the Australian shipment, he added that the company is “among the few Nasdaq-listed companies commercially supplying psi-lo-cybin to patients with treatment-resistant depression outside of clinical trials,” and noted no reports of serious adverse events from inception through December 31st, 2025. That is the tone throughout: fewer promises, more shipping records. The Strategic Shift Now Underway The next chapter is about funding it. On August 14th, 2026, the company established a discretionary $100Mn equity facility with Seven Knots, LLC. Draws are at the company’s discretion and capped at $2Mn each, with a price floor at 85% of the prior day’s close. That structure hands timing control to management rather than a counterparty. Where it points is the United States, a market the company describes itself as rescheduling ready to serve. Nothing there is settled, so treat it as a possibility rather than a plan. What is settled is the footprint already built. Sources: OPTH press releases dated May 20th, June 10th, and June 29th 7 Key Potential Catalysts For (Nasdaq: OPTH) Worth Reviewing #1. A Nasdaq Listing Backed By An Oversubscribed Raise. This profile joined the Nasdaq on May 20th, 2026, after a $15Mn raise priced at $6.25, and OPTH now carries a reporting profile many peers lack. #2. Revenue From Patients Rather Than From Grant Funding. Australia’s Therapeutic Goods Administration’s Authorized Prescriber Scheme has received 5mg capsules since September 2025, placing OPTH in a small group shipping commercially outside trials. #3. A Reported Share Float Under 5Mn Shares. Yahoo Finance lists a float of approximately 4.65Mn shares, so OPTH reads as a low float idea where the potential for heightened volatility may be significant. #4. One Licence Serving Both Commercial And Clinical Demand. The Princeton facility supplying Australian patients also cleared the first UK trial export, and OPTH runs both channels on one Health Canada licence. #5. A $100Mn Equity Facility Without Forced Drawdowns. The August facility with Seven Knots is discretionary and capped per draw, so OPTH sets the timing rather than a lender. #6. A New Microdose Line Aimed At Research Buyers. Standardized 1mg and 2mg capsules opened a second customer type in June, and OPTH supplies them from capacity it already operates. #7. A Cash Balance Sized Against A Small Market Value. Yahoo Finance reports roughly $13.07Mn of cash at June 30th, 2026, against a current market cap value near $25Mn (9/9/26), and OPTH carries that balance into its expansion plans. The Closing Word Regulated medicine rewards whoever can manufacture consistently once the rules change. Optimi Health Corp. (Nasdaq: OPTH) built that capability before the rules moved. Readers tracking heal-thcare transformation should put OPTH on the watch list and review its filings and news flow directly in the coming quarters. We’re kicking-off coverage on Optimi Health Corp. (Nasdaq: OPTH). Be on watch for updates heading your way shortly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. OPTIMI HEALTH CORP. (OPTH:US) (OPTI:CA) previously changed their symbols from OPTIMI HEALTH CORP. (OPTHF:US) (OPTI:CA) Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 09/09/2026 and ending on 09/10/2026 to publicly disseminate information about (OPTH:US) (OPTI:CA) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid fifteen thousand USD ("Funds"). These Funds were part of the eighty five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (OPTH:US) (OPTI:CA). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/opth-yijjb/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Constant Contact Data Notice